Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) Director Daniel Bradbury sold 2,400 shares of the firm's stock in a transaction on Monday, April 8th. The stock was sold at an average price of $20.45, for a total value of $49,080.00. Following the completion of the transaction, the director now owns 17,944 shares in the company, valued at $366,954.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Daniel Bradbury also recently made the following trade(s):
- On Thursday, April 4th, Daniel Bradbury sold 9,152 shares of Castle Biosciences stock. The stock was sold at an average price of $21.45, for a total value of $196,310.40.
- On Monday, March 4th, Daniel Bradbury sold 23,323 shares of Castle Biosciences stock. The stock was sold at an average price of $20.68, for a total value of $482,319.64.
- On Wednesday, February 7th, Daniel Bradbury sold 2,074 shares of Castle Biosciences stock. The stock was sold at an average price of $23.20, for a total value of $48,116.80.
Castle Biosciences Trading Down 5.2 %
CSTL stock opened at $20.43 on Thursday. The business's 50-day moving average price is $22.11 and its two-hundred day moving average price is $19.72. Castle Biosciences, Inc. has a 1-year low of $9.26 and a 1-year high of $26.70. The firm has a market cap of $560.80 million, a PE ratio of -9.46 and a beta of 0.93.
Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI
From Banyan Hill Publishing | Ad
Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.”
Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.
Click on Adam's shiny forehead for more details.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. The firm had revenue of $66.12 million for the quarter, compared to the consensus estimate of $51.32 million. On average, analysts forecast that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Scotiabank lifted their target price on Castle Biosciences from $33.00 to $37.00 and gave the stock a "sector outperform" rating in a report on Friday, March 1st. KeyCorp lifted their target price on Castle Biosciences from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Friday, March 1st. Finally, Guggenheim assumed coverage on Castle Biosciences in a report on Thursday, December 14th. They set a "buy" rating and a $25.00 target price on the stock.
Get Our Latest Research Report on Castle Biosciences
Institutional Trading of Castle Biosciences
Several hedge funds and other institutional investors have recently modified their holdings of CSTL. Rice Hall James & Associates LLC raised its stake in shares of Castle Biosciences by 3.7% in the 1st quarter. Rice Hall James & Associates LLC now owns 26,151 shares of the company's stock valued at $1,173,000 after purchasing an additional 938 shares during the period. JPMorgan Chase & Co. increased its position in shares of Castle Biosciences by 3.2% in the first quarter. JPMorgan Chase & Co. now owns 24,324 shares of the company's stock valued at $1,091,000 after acquiring an additional 754 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Castle Biosciences by 16.8% in the first quarter. Bank of New York Mellon Corp now owns 101,886 shares of the company's stock valued at $4,570,000 after acquiring an additional 14,658 shares during the last quarter. US Bancorp DE increased its position in shares of Castle Biosciences by 28.9% in the first quarter. US Bancorp DE now owns 16,468 shares of the company's stock valued at $739,000 after acquiring an additional 3,694 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its position in shares of Castle Biosciences by 16.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 12,966 shares of the company's stock valued at $582,000 after acquiring an additional 1,801 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
